Cancer Therapies

Phase I Clinical Trial Results Reported

Published in Cancer Weekly, June 1st, 1998

Onyx Pharmaceuticals, Inc., Richmond, California, reported results of two Phase I safety trials of its lead anticancer viral therapeutic, ONYX-015, in pancreatic cancer and in gastrointestinal cancers that have metastasized to the liver.

In both studies, ONYX-015 was found to be safe and well-tolerated, as well as biologically active in the pancreatic study. Based on these results, Onyx is planning to initiate further studies in both cancer types using novel routes of administration and regimens, including combining ONYX-015 with standard chemotherapy.

Results of the two studies were presented at the American Society of Clinical Oncology (ASCO)...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (1998-06-01)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry